{"DataElement":{"publicId":"3128320","version":"1","preferredName":"Breast Tumor Clinical M Stage","preferredDefinition":"Code to signify the absence or presence of distant metastases from breast cancer as determined prior to treatment based on evidence obtained from clinical assessment parameters (physical examination, imaging, endoscopy, biopsy, surgical exploration, etc.).","longName":"2188689v1.0:3128317v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2188689","version":"1","preferredName":"Breast Tumor Clinical M Stage","preferredDefinition":"Information related to clinical M stage for a breast tumor.","longName":"BRST_TUMOR_C_M","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2206465","version":"1","preferredName":"Breast Neoplasm","preferredDefinition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.:(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.","longName":"C12971:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast","conceptCode":"C12971","definition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F64A-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207806","version":"1","preferredName":"Clinical M Stage","preferredDefinition":"Having to do with the examination and treatment of patients.:One criteria of the TMN staging system.  M refers to the presence of metastasis.","longName":"C25398:C25727","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical","conceptCode":"C25398","definition":"Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"M Category","conceptCode":"C25727","definition":"One criteria of the TNM staging system. M refers to the presence of metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-30E1-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E53F0DC4-6E65-6553-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-29","modifiedBy":"TAYLORT","dateModified":"2017-11-17","changeDescription":"11/17/17 tt associated with CS/CSI. 9/13/17 tt transferred context; changed def - 1st letter upper case; changed Reg Status to Qualified. CSI? \"","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3128317","version":"1","preferredName":"Breast Tumor M Stage","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.   --2002_One criteria of the TMN staging system.  M refers to the presence of metastasis.","longName":"3128317v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"M1","valueDescription":"Distant detectable metastases as determined by classic clinical and radiographic means and/or histologically proven larger than 0.2 mm","ValueMeaning":{"publicId":"3128319","version":"1","preferredName":"Distant detectable metastases as determined by classic clinical and radiographic means and/or histologically proven larger than 0.2 mm","longName":"3128319","preferredDefinition":"Distant detectable metastases as determined by classic clinical and radiographic means and/or histologically proven larger than 0.2 mm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DA6F4B8-2B79-0DE1-E040-BB89AD43442B","latestVersionIndicator":"Yes","beginDate":"2010-08-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DA6F4B8-2B92-0DE1-E040-BB89AD43442B","beginDate":"2010-08-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-12","modifiedBy":"ONEDATA","dateModified":"2010-08-12","deletedIndicator":"No"},{"value":"M0","valueDescription":"No distant metastases","ValueMeaning":{"publicId":"2559521","version":"1","preferredName":"No distant metastases","longName":"2559521","preferredDefinition":"No clinical or radiographic evidence of distant metastases","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B58E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"REEVESD","dateModified":"2010-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DA6F4B8-2B9C-0DE1-E040-BB89AD43442B","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-12","modifiedBy":"ONEDATA","dateModified":"2010-08-12","deletedIndicator":"No"},{"value":"cM0(i+)","valueDescription":"No clinical or radiographic evidence of distant metastases, but deposits of molecularly or microscopically detected tumor cells in circulating blood, bone marrow or other non-regional nodal tissue that are no larger than 0.2 mm","ValueMeaning":{"publicId":"3152456","version":"1","preferredName":"No clinical or radiographic evidence of distant metastases, but deposits of molecularly or microscopically detected tumor cells in circulating blood, bone marrow or other non-regional nodal tissue that are no larger than 0.2 mm","longName":"3152456","preferredDefinition":"No clinical or radiographic evidence of distant metastases, but deposits of molecularly or microscopically detected tumor cells in circulating blood, bone marrow or other non-regional nodal tissue that are no larger than 0.2 mm in a patient without symptoms or signs of metastases","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9339DE92-407A-9BF1-E040-BB89AD437554","latestVersionIndicator":"Yes","beginDate":"2010-10-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9339DE92-4093-9BF1-E040-BB89AD437554","beginDate":"2010-08-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-22","modifiedBy":"ONEDATA","dateModified":"2010-10-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3128316","version":"1","preferredName":"Breast Carcinoma M Stage Stage","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002:One criteria of the TMN staging system.  M refers to the presence of metastasis.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C4872:C25727:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"M Category","conceptCode":"C25727","definition":"One criteria of the TNM staging system. M refers to the presence of metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DA6F4B8-2B2F-0DE1-E040-BB89AD43442B","latestVersionIndicator":"Yes","beginDate":"2010-08-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-12","modifiedBy":"ONEDATA","dateModified":"2010-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC:American Joint Committee on Cancer Cancer Staging Manual, 7th Ed., 2009","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DA6F4B8-2B40-0DE1-E040-BB89AD43442B","latestVersionIndicator":"Yes","beginDate":"2010-08-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-12","modifiedBy":"REEVESD","dateModified":"2010-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044924","version":"1","longName":"Inactive CDEs as of March 2017","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Clinical M Stage","type":"Preferred Question Text","description":"Clinical M Stage","url":null,"context":"NCIP"}],"origin":"AJCC:American Joint Committee on Cancer Cancer Staging Manual, 7th Ed., 2009","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8DA6F4B8-2BA6-0DE1-E040-BB89AD43442B","latestVersionIndicator":"Yes","beginDate":"2010-08-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-12","modifiedBy":"TSESU","dateModified":"2018-07-17","changeDescription":"Curated for The Cancer Genome Atlas (TCGA) by request of T. Lichtenberg 8/2010","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}